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IL-10-producing CD4
1 type 1 regulatory T (Tr1) cells, deﬁned based on their ability to
produce high levels of IL-10 in the absence of IL-4, are major players in the induction and
maintenance of peripheral tolerance. Tr1 cells inhibit T-cell responses mainly via cyto-
kine-dependent mechanisms. The cellular and molecular mechanisms underlying the
suppression of APC by Tr1 cells are still not completely elucidated. Here, we deﬁned that
Tr1 cells speciﬁcally lyse myeloid APC through a granzyme B (GZB)- and perforin (PRF)-
dependent mechanism that requires HLA class I recognition, CD54/lymphocyte function-
associated antigen (LFA)-1 adhesion, and activation via killer cell Ig-like receptors (KIRs)
and CD2. Notably, interaction between CD226 on Tr1 cells and their ligands on myeloid
cells, leading to Tr1-cell activation, is necessary for deﬁning Tr1-cell target speciﬁcity. We
also showed that high frequency of GZB-expressing CD4
1 T cells is detected in tolerant
patients and correlates with elevated occurrence of IL-10-producing CD4
1 T cells. In
conclusion, the modulatory activities of Tr1 cells are not only due to suppressive cytokines
but also to speciﬁc cell-to-cell interactions that lead to selective killing of myeloid cells and
possibly bystander suppression.
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Introduction
CD4
1 type 1 regulatory T (Tr1) cells are adaptive IL-10-producing
Tregs fundamental in controlling immune responses and in
inducing peripheral tolerance both in humans and mice [1, 2].
The ﬁrst indication that Tr1 cells mediate peripheral tolerance in
vivo came from SCID patients who developed long-term tolerance
to stem cell allograft [1]. After that, Tr1 cells have been found to
be induced in a variety of in vivo settings [3]. Tr1 cells have been
recently associated with the induction of persistent mixed
chimerism (PMC) in b-thalassemic (b-thal) patients after HLA
identical hematopoietic stem cell transplantation (HSCT) [4].
Tr1 cells are induced in the periphery upon chronic Ag
stimulation in the presence of IL-10 derived from tolerogenic APC
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far. Therefore, Tr1 cells can be characterized based on their
speciﬁc cytokine production proﬁle (IL-10
1, TGF-b
1, IL-4
,
IL-2
low, and IFN-g
low). Tr1 cells are Ag-speciﬁc, hypo-responsive,
and suppress effector T cells mainly by the release of IL-10 and
TGF-b [2]. It has been hypothesized that a cell-contact-dependent
mechanism cooperates with the release of immunosuppressive
cytokines in inhibiting immune responses by Tr1 cells, since the
addition of neutralizing antibodies against IL-10R and TGF-b did
not completely revert suppression mediated by Tr1 cells [5].
Murine CD25
1 Treg cells express granzyme B (GZB) [6, 7],
and induce apoptosis of T and NK cells [8, 9], indicating that
GZB-dependent killing of T cells represents one of the mechan-
isms responsible for Treg-mediated suppression. In line with
these ﬁndings, CD25
1 Tregs isolated from GZB-deﬁcient mice
have reduced suppression ability compared to CD25
1 Tregs from
wild type mice [8].
Human naturally occurring Tregs (nTregs) or adaptive IL-10-
producing Tregs, depending on the mode of activation/genera-
tion, can express both granzyme A (GZA) and GZB [10–12].
nTregs express GZA or GZB when activated in the presence of low
or high concentrations of IL-2, respectively [10, 11]. IL-10-
producing Tregs generated in vitro by activating CD4
1 T cells
with anti-CD3 and anti-CD46 mAb express only GZB [10],
whereas IL-10-producing Tregs induced by HSV-stimulated
human plasmacytoid DCs express both GZA and GZB [13].
nTregs activated with CD3/CD28 and IL-10-producing Tregs
activated with CD3/CD46 were shown to kill different target cells
through the adhesion of CD18 [10].
In the present study, we investigated the cellular and mole-
cular mechanisms underneath Tr1-mediated cytotoxicity. Results
show that polarized Tr1-cell lines and Tr1-cell clones express and
release high levels of GZB in an IL-10-dependent manner, and
lyse APC via GZB and perforin (PRF). Lysis mediated by Tr1 cells
requires HLA class I recognition, lymphocyte function-associated
antigen (LFA)-1-mediated adhesion, and stimulation via CD2 and
CD226, and consequently is restricted to myeloid APC that
express high levels of the ligands of LFA-1 (CD54), of CD2
(CD58), and of CD226 (CD155). GZB
1CD4
1 T cells are detected
in the periphery of multiple-transfused b-thal patients and in
PMC b-thal patients in whom Tr1 cells are present at high
frequency, supporting the hypothesis that GZB is relevant also for
the in vivo function of Tr1 cells.
Results
Human Tr1 cells express and release high levels of GZB
Tr1 polarized cell lines expressed signiﬁcantly higher levels of
GZB compared to Th0-cell lines (97.3 versus 12.9%, n511,
po0.0001, Fig. 1A). Notably, IL-10-producing Tr1 cells represent
10–15% of the polarized population, thus GZB expression is not
restricted to this population of cells (Fig. 1B). Tr1-cell lines
express also signiﬁcantly higher levels of GZA compared to Th0-
cell lines (58.7% versus 9%, n58, po0.0001, not shown),
nevertheless its expression was consistently lower than that of
GZB. Tr1-cell lines contained a signiﬁcantly higher percentage of
PRF
1 cells compared to Th0-cell lines before (8.8 versus 1.8%,
n57, p50.015) and after stimulation (13.3 versus 5.1%, n57,
p50.007, not shown).
Tr1-cell clones, isolated from peripheral blood of two distinct
healthy donors (HD) and deﬁned based on IL-10/IL-4 ratio Z8
(Table 1), expressed higher levels of GZB compared to Th0-cell
clones (Fig. 1C). The MFI of GZB expression was variable among
both Tr1- and Th0-cell clones, but it correlated with the amounts
of IL-10 produced by Tr1- but not Th0-cell clones (Fig. 1D),
suggesting a relationship between the presence of IL-10 in Tr1-
cell culture and GZB expression.
Ex vivo isolated CD4
1IL-10
1 T cells contained a higher
percentages of GZB
1 cells compared to CD4
1IL-10
 T cells
(20.6 % versus 2.4%, Supporting Information Fig. 1), indicating
that also circulating Tr1 cells express GZB. However, it should be
considered that to isolate CD4
1IL-10
1 T cells, peripheral blood
cells are pre-activated and, as shown in Fig. 1A GZB expression
decreased in activated Tr1 cells. Thus, the percentage of GZB
observed in ex vivo isolated CD4
1IL-10
1 T cells probably does
not mirror the in vivo situation.
Tr1-cell lines spontaneously released signiﬁcantly higher
levels of GZB compared to Th0-cell lines (3910
3 versus
0.510
3 SFU/10
6 cells, in Tr1 and Th0 cells, n55, p50.006,
Fig. 1E). GZB released by Tr1-cell lines was further increased
upon activation (Fig. 1E). Puriﬁed IL-10-producing Tr1 cells
secreted signiﬁcantly higher amounts of GZB compared to the
original Tr1-cell lines (13210
3 versus 3210
3 SFU/10
6 cells,
n53, p50.05, Fig. 1F), indicating that IL-10-producing
Tr1 cells are the main GZB producers in culture. Notably, GZB
expression in puriﬁed IL-10-producing Tr1 cells was higher
compared to that of non-IL-10-producing T cells contained in
polarized Tr1-cell population (data not shown), sustaining the
conclusion that GZB expression in non-IL-10-producing
T cells present in Tr1-polarized populations is the result of
exposure to IL-10-derived from Tr1 cells. Overall, these data
demonstrate that Tr1 cells expressed and released high levels of
GZB in an IL-10-dependent manner, and that non-IL-10-produ-
cing T cells present in the polarized cultures expressed GZB as a
result of IL-10 exposure.
Tr1 cells speciﬁcally kill myeloid cells
Tr1-cell lines efﬁciently lysed U937 cells, a monocytic cell line,
but not K562 cells, an erythroleukemic cell line (Fig. 2A), or
Daudi, a B lymphoblast cell line, or Jurkat, a T leukemic cell line
(Supporting Information Fig. 2). Th0-cell lines exerted limited
lytic activity on the cell lines tested (Fig. 2A and Supporting
Information Fig. 2).
When Tr1 cells were co-cultured with U937 cells, high
percentage of CD107a
1GZB
1 cells was observed (on average
26% of CD107a
1GZB
1 cells in Tr1 cells cultured with U937
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& 2011 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.eji-journal.euFigure 1. Tr1 cells express and release GZB. (A) GZB expression was determined in Th0- and Tr1-cell lines unstimulated (unstim) or stimulated
with PMA (10ng/mL; Sigma) plus IONO (ionomycin) (150ng/mL; Sigma) for 6h. One donor representative of 11 unstimulated donors and of ﬁve
stimulated donors tested is shown. Numbers represent percentage of positive cells and MFI in bracket. (B) Alternatively, IL-10, IL-4, and GZB
expression was determined upon stimulation with Leukocyte Activation Cocktail (BD Pharmingen) for 5h. One donor out of six donors tested is
shown. Numbers represent percentage of positive cells. (C) GZB expression was determined in four unstimulated Tr1- and Th0-cell clones.
Numbers represent percentage of positive cells and MFI in bracket. (D) Plot represents IL-10 production expressed as pg/mL versus MFI of GZB
expression in each of ten Tr1-cell clones and of nine Th0-cell clones tested. The line represents the linear regression. The p value of the correlation
and the coefﬁcient of determination (r
2) are reported (two-tailed test). (E) GZB release by unstimulated (unstim) and stimulated with PMA/IONO
Tr1- and Th0-cell lines was measured by ELISPOT. The Y-axis represents the number of SFU/10
6 cells. (F) GZB release by original Tr1-cell lines, and
puriﬁed IL-10-producing cells was measured by ELISPOT. Mean7SE of GZB spots normalized to 10
6 cells of ﬁve (unstim), three (PMA/IONO), and
three (F) independent experiments performed in duplicate is shown. SFU, spot forming units pr0.05, and pr0.005 (one-tailed test).
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consistent with the lysis assessed by
51Cr assay (Fig. 2A). As
expected, percentages of CD107a
1GZB
1 cells within the Tr1 cells
co-cultured with K562, Daudi, or Jurkat cells were low and
similar to those observed in Tr1 cells cultured alone (Fig. 2B and
not shown). Despite the ability of Th0-cell lines to degranulate
when activated with U937 cells, as demonstrated by CD107a
staining, they were unable to lyse these target cells. The
percentages of CD107a
1GZB
1 cells were indeed similar to those
of observed in Tr1-cell cultures alone (Fig. 2B).
Four different Tr1-cell clones efﬁciently lysed U937 but not
K562 cells (Fig. 2C and D and not shown). Tr1 clone ]4, that
displayed the highest lytic ability (Fig. 2C), had also the highest
GZB expression (99.7%, MFI 4383, Fig. 2D left panel) and
secreted the highest level of IL-10 (6528pg/mL, Table 1),
whereas Tr1 clone ]5 had the lowest lytic ability (Fig. 2C),
the lowest GZB expression (39%, MFI 798, Fig. 2D left
panel), and secreted the lowest levels of IL-10 (590pg/mL,
Table 1). Tr1 clones ]1 and ]3 killed U937 cells similarly
(Fig. 2C) and had similar levels of GZB (81% MFI 1519 and
67.6% MFI 915, respectively, Fig. 2D left panel) and IL-10
production (2015pg/mL and 1818pg/mL, respectively, Table 1).
The percentages of CD107a
1GZB
1 cells in Tr1-cell clones were
higher (Fig. 2D) compared to Tr1-cell lines (Fig. 2B), consistent
with the fact that Tr1-cell clones are a homogeneous population
of IL-10-producing T cells. Notably, Th0-cell clones efﬁciently
lysed U937 cells (Supporting Information Fig. 3) but cytotoxicity
was independent of the levels of GZB expression and of their
ability to secrete IL-10 (Fig. 1D left panel). These data demon-
strated that GZB expression by Tr1 cells correlates not only with
IL-10 production but also with their lytic activity against myeloid
cell line.
Tr1-cell lines degranulate in the presence of freshly isolated
CD14
1 and CD1c
1 cells, but not CD19
1 and CD3
1 T cells
(both allogeneic and autologous, Fig. 3 and Supporting Infor-
mation Fig. 4A). The mean percentages of CD107a
1GZB
1 cells in
Tr1-cell lines co-cultured with autologous CD14
1 cells or CD1c
1
cells were 27% and 18%, respectively. Similar results were
obtained when Tr1-cell lines were co-cultured with allogeneic
CD14
1 cells (21%) and CD1c
1 cells (18%). Of note, mean
percentages of CD107a
1GZB
1 cells in Tr1-cell lines co-cultured
with autologous or allogeneic CD3
1 T cells were 7% (n54, Fig.
3) and 6% (n53, Supporting Information Fig. 4A), respectively.
Analysis of Annexin V and 7-aminoactinomycin D (7-ADD)
staining conﬁrmed that, while CD14
1 cells are killed, CD3
1
T cells are not killed when co-cultured with Tr1-cell lines
(Supporting Information Fig. 4B).
Overall these ﬁndings demonstrate that Tr1-cell lines
speciﬁcally kill both autologous and allogeneic cells of myeloid
origin.
Tr1-mediated cytotoxicity is dependent on GZB and
PRF, and requires HLA class I recognition
The role of GZB in the lytic activity mediated by Tr1 cells was
demonstrated by the addition of Z-AAD-CMK, an inhibitor of
GZB, which completely abrogated the cytotoxic activity of Tr1
cells in a dose-dependent manner (Fig. 4A). Similarly, Tr1-
mediated cytotoxicity was nearly abolished when CMA, a PRF
Table 1. Cytokine proﬁle of T-cell clones
a)
IL-2pg/mL IL-4pg/mL IL-10pg/mL IFN-g pg/mL IL-17pg/mL
Tr1]14 8 o9 2015 2205 o30
Tr1]2 o15 37 1558 7942 o30
Tr1]3 185 o9 1818 11015 67
Tr1]4 o15 728 6528 7093 o30
Tr1]5 o15 o9 590 766 o30
Tr1]6 126 97 3808 6187 218
Tr1]7 o15 22 3941 1796 59
Tr1]8 o15 o9 4160 52684 90
Tr1]9 o15 757 12500 3723 o30
Tr1]10 170 127 959 967 o30
Th0]12 2 43000 o19 469 o30
Th0]2 105 1446 o19 1895 o30
Th0]3 132 2105 o19 3099 o30
Th0]4 o15 145 336 3124 o30
Th0]5 294 43000 o19 2615 o30
Th0]6 41000 43000 574 2567 o30
Th0]7 527 2523 506 2833 o30
Th0]8 1211 2597 o19 3099 o30
Th0]9 362 212 o19 1799 o30
a) Tr1 and Th0 cell clones were stimulated with immobilized anti-CD3 mAb and soluble anti-CD28 mAb. Culture supernatants were collected after
24h (IL-2) and 48h (IL-4, IL-10, IFN-g, and IL-17) and cytokine levels were measured by ELISA.
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are required for Tr1-cell-mediated killing.
Addition of a pan anti-HLA-I mAb (clone W6/32) signiﬁcantly
inhibited, in a dose-dependent manner, the killing of U937,
CD14
1, and CD1c
1 cells (autologous and allogeneic) by Tr1-cell
lines and by three distinct Tr1-cell clones (Fig. 5A–C and data not
shown). Tr1 cells express a variety of activating killer cell Ig-like
receptors (KIRs) including KIR2DS2, KIR2DS3, KIR3DS1, and
KIR2DL4, the ligand speciﬁc for HLA-G (Table 2). Addition of
neutralizing anti-HLA-G mAb (clone 87G) partially inhibited, in a
dose-dependent manner, the killing of U937, CD14
1, and CD1c
1
cells by both Tr1-cell lines (Supporting Information Fig. 5A and
B) and Tr1-cell clones (Supporting Information Fig. 5C),
supporting the contribution of stimulatory KIRs in promoting the
killing of target cells.
Thus, similar to the NK-mediated killing, Tr1 cells, despite the
fact that they are CD4
1 T cells, require Ag-nonspeciﬁc HLA class I
recognition and activation via KIRs to lyse target cells.
Figure 2. Tr1-cell lines and Tr1-cell clones speciﬁcally lyse target cell of monocytic origin. (A) The cytotoxic activity of Tr1- and Th0-cell lines
against U937 and K562 target cells was determined by
51Cr release. NK cells from the same HD were used as positive controls. Mean7SE of six
donors for U937 and of ﬁve for K562 performed in duplicate are reported. (B) Tr1- and Th0-cell lines were co-cultured with U937 and K562 target
cells at 10:1 E:T ratio. Degranulation in the presence of GZB was measured by co-expression of CD107a and GZB in CD4
1 T cells. NK cells from the
same HD were used as positive controls. One donor representative of ten donors performed in eight independent experiments for U937 and of four
donors performed in three independent experiments for K562 is shown. Numbers represent percentage of CD107a
1GZB
1 cells. (C) Cytotoxic
activity of four Tr1-cell clones against U937 target cell was determined by
51Cr release. (D) In parallel, Tr1-cell clones were co-cultured with U937
target cell at 10:1 (E:T) ratio and degranulation in the presence of GZB was measured by co-expression of CD107a and GZB in CD4
1 T cells. Numbers
represent percentage of CD107a
1GZB
1 cells.
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adhesion and activation via CD2 and CD226
To dissect the molecular mechanism underlying the target
speciﬁcity of Tr1 cells, we investigated adhesion and signaling
molecules involved in Tr1-myeloid APC interaction. Both CD14
1
and CD1c
1 cells expressed higher levels of CD54 compared to
T and B cells (not shown), and Tr1 cells expressed LFA-1 (CD18/
CD11a), the CD54 ligand (Supporting Information Fig. 6).
Addition of neutralizing anti-CD18 mAb blocked degranulation
of Tr1-cell lines when co-cultured with CD14
1 or CD1c
1 cells
(Fig. 6A). CD54 expression on target cells is speciﬁcally involved
in the formation of a stable immunological synapse essential
for cytotoxicity mediated by NK cells and CTLs [14].
Therefore, our ﬁndings suggest that the high expression of
CD54 on myeloid cells is responsible for the formation of a stable
and prolong interaction with Tr1 cells, leading to lysis of the
target cell.
We next investigated whether CD2, which is implicated not
only in the adhesion between NK cells and its target cells, but also
in NK-cell activation [15], contributes to Tr1-cell activation. Anti-
CD2-bearing p815 cells promoted a strong Tr1-cell degranulation
in the presence of GZB, whereas they induced degranulation of
Th0 cells in the absence of GZB (Fig. 6B). Notably, CD58 is
expressed at high levels in both CD14
1 and CD1c
1 cells (not
shown) and Tr1 cells are CD2 positive (Supporting Information
Fig. 6). These results demonstrate that activation of Tr1 cells via
CD2 is required for cytotoxic activity mediated by Tr1 cells and
Figure 3. Tr1-cell lines speciﬁcally lyse primary monocytes and myeloid DCs. Tr1- and Th0-cell lines were co-cultured with allogeneic freshly
isolated CD19
1, CD14
1, CD3
1, and CD1c
1 cells at 10:1 (E:T) ratio, and degranulation in the presence of GZB was measured by co-expression of
CD107a and GZB in CD4
1 T cells. One donor out of four (CD19
1), three (CD14
1), three (CD3
1), and four (CD1c
1) donors performed in two
independent experiments is shown. Numbers represent percentage of CD107a
1GZB
1 cells.
Figure 4. Tr1-mediated cytotoxicity is GZB- and PRF-dependent. Tr1-
cell lines were pre-incubated with Z-AAD-CMK at the indicated
concentrations (A) or with CMA (100nM) (B), co-cultured with U937
target cell at 100:1 (E:T) ratio, and cytotoxicity was determined by
51Cr
release. Mean7SE of three donors are reported.
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of myeloid cells.
DNAM-1 (CD226) is an adhesion/signaling molecule that
contributes to the NK-mediated lysis of DCs [16]. Tr1-cell lines
and Tr1-cell clones express high levels of CD226 (Supporting
Information Fig. 6 and data not shown), and CD155 and CD112,
the ligands of CD226, are speciﬁcally expressed on myeloid APC
[17]. We thus investigated whether CD226 contributed to Tr1-
mediated lysis of myeloid cells. Anti-CD226-bearing p815 cells
promoted Tr1-cell degranulation in the presence of GZB, whereas
they did not induce degranulation of Th0 cells (Fig. 6C). More-
over, addition of anti-CD226 mAb signiﬁcantly increased degra-
nulation of Tr1 cells when co-cultured with CD14
1 cells (21%
versus 16% of CD107a
1GZB
1 cells in cultures in the presence or
absence of anti-CD226, respectively, p50.0016, Supporting
Information Fig. 7). Similar results were obtained when CD1c
1
cells were used as target cells (18% versus 15% of CD107a
1GZB
1
cells in cultures in the presence or absence of anti-CD226,
respectively, p50.02, Supporting Information Fig. 7). These
results demonstrate that activation via CD226 is required for
cytotoxicity mediated by Tr1 cells, and that speciﬁc interaction
between CD155 and CD112 on myeloid cells and CD226 on Tr1
cells leads to Tr1-cell activation and degranulation.
In vivo correlation between high percentages of
GZB-expressing and IL-10-producing CD4
1 T cells
We next investigated whether the relation between GZB
expression and IL-10-producing Tr1 cells occurs also in vivo.
We showed that IL-10 production and presence of Tr1 cells
correlate with PMC in b-thal patients after HSCT ([4] and data
not shown). In peripheral blood of these PMC patients, the
Figure 5. Tr1-mediated cytotoxicity is HLA class I-dependent. (A) Tr1-cell lines were co-cultured with U937 target cell line at 100:1 (E:T) ratio in the
presence of anti-HLA class I mAb or IgG2a,k isotype control at the indicated concentrations, and cytotoxicity was determined by
51Cr release.
Mean7SE of four donors performed in two independent experiments are reported. (B) Tr1-cell lines were co-cultured with freshly isolated
autologous CD14
1 and CD1c
1 cells at 10:1 (E:T) ratio in the presence of anti-HLA-I mAb or IgG2a,k isotype control, and degranulation in the
presence of GZB was measured by co-expression of CD107a and GZB in CD4
1 T cells. One donor representative of three donors performed in a
single experiment is shown. Numbers represent percentage of CD107a
1GZB
1 cells. (C) Tr1-cell clones were co-cultured with U937 target cell at 10:1
(E:T) ratio in the presence of anti-HLA-I mAb or IgG2a,k isotype control, and degranulation was measured by co-expression of CD107a and GZB in
CD4
1 T cells. Numbers represent percentage of CD107a
1GZB
1 cells.
Table 2. Tr1-cell lines express activating KIRs
a)
Th0 HD1 Tr1 HD1 Th0 HD2 Tr1 HD2
KIR2DL4 11 11
KIR2DS1  1 
KIR2DS2 11 11
KIR2DS3 11 
KIR2DS4  
KIR2DS5  
KIR3DS1  11
a) mRNA expression of human activating KIR genes was assessed in
Th0 and Tr1 T-cell lines by KIR typing. Clear visibility (1) or absence
() of KIR-speciﬁc PCR products of two distinct donors tested are
shown.
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1GZB
1 T cells was higher compared to HD
before and after stimulation (7.9% versus 3.9%, p50.04 and
24% versus 3.5%, p50.0001, respectively), and associated with
higher frequencies of IL-10-producing CD4
1 T cells [4] (Support-
ing Information Fig. 8A and B). Similar results were obtained by
analyzing peripheral blood of b-thal patients tolerized after
repetitive exposure to allo-Ag during multiple transfusions and
prior-HSCT (Supporting Information Fig. 8C and D, and Fig. 9).
Importantly, a correlation between the percentages of
CD4
1GZB
1 T cells and the frequencies of IL-10-producing
CD4
1 T cells in PBMCs from both patients and HD was observed
(Supporting Information Fig. 8E), suggesting that IL-10 modu-
lates GZB expression also in vivo. Overall, these results indicate
that in two different clinical conditions associated with tolerance,
the presence of IL-10-producing cells correlates with GZB-
expressing cells.
Discussion
In this study, we deﬁne the cellular and molecular mechanisms
underlying the cytotoxicity mediated by human Tr1 cells. We
demonstrate that human Tr1 cells, in vitro generated and ex vivo
isolated, express and release high levels of GZB, and speciﬁcally
lyse target cells of myeloid origin, but not T and B lymphocytes.
The mechanism of Tr1-mediated cytotoxicity is dependent on
GZB and PRF, requires HLA class I recognition, LFA-1-mediated
adhesion, and activation via KIRs, CD2, and CD226. GZB
expression correlates with the amounts of IL-10 produced by
Tr1 cells in vitro and in vivo, since high frequencies of IL-10-
producing CD4
1 T cells in tolerant b-thal patients are associated
with elevated occurrence of CD4
1GZB
1 T cells. These results
demonstrate that, in addition to suppression of effector T cells via
cytokine secretion, expression of PD-1 and CTLA-4 [18] and
adenosine production [19], a key function of Tr1 cells is the GZB-
dependent killing of myeloid cells.
Tr1-cell clones isolated from PMC b-thal patients express
higher levels of GZB compared to Th0-cell clones [4]. Further-
more, IL-10-producing Tregs generated by CD3/CD46 cross-
linking, preferentially express GZB and lyse different target cells
[10]. In the present study, we show that IL-10-producing Tr1
cells, generated in vitro or ex vivo isolated, not only express, but
also secrete GZB, which mediates the cytotoxic activity of Tr1
cells. Furthermore, we demonstrate for the ﬁrst time that Tr1
cells speciﬁcally kill cells of myeloid origin.
Despite the fact that Tr1 cells are CD4
1 T cells, they require
recognition and activation via HLA class I molecules expressed on
target cells to lyse myeloid cells, indicating that cytotoxicity
mediated by Tr1 cells is Ag-independent. This mechanism of
target recognition by Tr1 cells resembles the Ag-nonspeciﬁc-
mediated recognition and activation of NK cells [20], and is
opposed to the Ag-speciﬁc activation of CD8
1 and CD4
1 CTLs
[21–23]. However, in contrast to NK cells, which kill target cells
lacking HLA class I molecules when regulation mediated by
inhibitory receptors (i.e. KIRs) is missing, Tr1 cells kill target cells
upon HLA class I molecule recognition and subsequent activation,
indicating that Tr1-mediated cytotoxicity is triggered by activa-
tory receptors recognizing HLA class I. In line with this ﬁnding,
we showed that Tr1 cells express different activatory KIRs, which
are probably involved in their activation and consequent lytic
activity [24, 25].
The myeloid cell killing by Tr1 cells is attributable to the high
levels of CD54, CD58, CD155, and CD112 on CD14
1 and CD1c
1
cells. CD54/LFA-1 and CD58/CD2 interactions not only contri-
bute to a stable adhesion leading to the formation of lytic
immunological synapse by NK cells [26], but also participate in
their activation [27–29]. Neutralizing mAb against CD18 efﬁ-
ciently abrogates the Tr1-mediated cytotoxicity, and activation of
Figure 6. Tr1-mediated cytotoxicity requires CD18 adhesion and activation via CD2 and CD226. (A) Tr1-cell lines were co-cultured with freshly
isolated allogeneic CD14
1 and CD1c
1 cells at 10:1 (E:T) ratio in the presence of anti-CD18 mAb or IgG1 isotype control, and degranulation in the
presence of GZB was measured by co-expression of CD107a and GZB in CD4
1 T cells. One donor representative of three donors tested in two
independent experiments is shown. Numbers represent percentage of CD107a
1GZB
1 cells. (B) Tr1- and Th0-cell lines were co-cultured with p815
cells pre-incubated with anti-CD2 mAb at 10:1 (E:T) ratio, and degranulation was determined by co-expression of CD107a and GZB in CD4
1 T cells.
One donor representative of three donors performed in two independent experiments is shown. Numbers represent percentage of CD107a
1GZB
1
cells. (C) Tr1- and Th0-cell lines were co-cultured with p815 cells pre-incubated with anti-CD226 mAb at 10:1 (E:T) ratio, and degranulation was
determined by co-expression of CD107a and GZB in CD4
1 T cells. One donor out of ﬁve donors performed in two independent experiments is
shown. Numbers represent percentage of CD107a
1GZB
1 cells.
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TCR engagement. Thus, despite the need for Tr1 cells to be
activated via their TCR to secrete the immunomodulatory cyto-
kines IL-10 and TGF-b, and exert their speciﬁc suppressive
activity, once activated, Tr1 cells acquire GZB expression and lyse
myeloid cells in an Ag-nonspeciﬁc CD2-mediated manner. This
effect concurs with the activation of Tr1 cells via CD226-medi-
ated signaling, and results in the polarized degranulation and
release of both GZB and PRF, and in myeloid cell killing. CD226 is
known to be critically involved in the NK-mediated killing of
myeloid APCs, since CD155 and CD112, the ligands of CD226,
are speciﬁcally expressed by monocytes and myeloid DCs [16, 17,
30–32]. Since Tr1 cells express LFA-1, CD2, and CD226, we can
speculate that their target speciﬁcity depends upon the array and
density of expression of their ligands, CD54, CD58, and impor-
tantly, CD155 and CD112 on myeloid cells. The combination of
signaling through these receptors, in association with activation
by KIRs, is necessary to achieve the threshold required to properly
activate Tr1-cell lytic activity. Moreover, our results showed that
CD226 not only concurs with activation of Tr1 cells, but also
confers their myeloid target cell speciﬁcity.
In the present study, we also demonstrated that the expres-
sion of GZB by Tr1-cell lines and cell clones correlates and is
intrinsically associated with the presence of IL-10 in culture. The
direct role of IL-10 in promoting and maintaining GZB expression
in CD4
1 T cells in vitro is supported by previous reports [13, 33]
and by results obtained with PBL cultured in the presence of
IL-10, which upregulated GZB (Seraﬁni G., unpublished obser-
vations), and with human CD4
1 T cells transduced with a lenti-
viral vector encoding for human IL-10, which constitutively
express high levels of GZB (Andolﬁ G., unpublished observation).
Here, we demonstrate that GZB expression by Tr1-cell clones is
dependent on their autocrine IL-10 production. Tr1 cells are Ag-
speciﬁc and produce IL-10 upon TCR stimulation [3]. Thus, GZB
expression by Tr1 cells is speciﬁc and occurs primarily when Tr1
cells are activated. This effect is independent of TGF-b and
opposed to that observed in murine CD8
1 CTLs [34]. In line with
these in vitro observations are in vivo results, where high
expression of GZB is associated with circulating IL-10-producing
T cells. Similarly, high frequency of IL-10-producing T cells [4]
and CD4
+GZB
+ T cells is observed in tolerant patients (PMC and
poly-transfused b-thal patients). Thus, these ﬁndings indicate
that GZB is associated with IL-10 in vitro and in vivo, and can be
used as surrogate marker for Tr1 cells in vivo.
Tr1 cells suppress T-cell responses mainly via IL-10 and
TGF-b, secreted upon Ag-speciﬁc TCR activation. These immu-
nomodulatory cytokines directly inhibit effector T-cell prolifera-
tion and expression of HLA class II and costimulatory molecules
on APC, which indirectly suppress effector T cells [3]. We now
provide evidence that IL-10 produced by Tr1 cells upon TCR
activation also directly induces GZB expression in Tr1 cells, which
in turn acquire the ability to kill monocytes and myeloid DCs in
an Ag-nonspeciﬁc manner. Based on these ﬁndings, we propose
that selective depletion of myeloid APC by Tr1 cells, during an
active immune response, represents an additional bystander
mechanism of suppression that ampliﬁes the tolerogenic loop
induced by IL-10 and TGF-b produced by Tr1 cells.
Materials and methods
Material and methods are reported in full as Supporting
Information (available on the European Journal of Immunology
website).
Human peripheral blood was obtained from HD upon
informed consent in accordance with local ethical committee
approval (TIGET PERIBLOOD) and with the World Medical
Association’s Helsinki Declaration.
T-cell differentiation
Tr1- and Th0-cell lines were differentiated using murine L cells
transfected with hCD32, hCD80, and hCD58 and supplemented
with anti-CD3 mAb (100ng/mL; OKT3, Jansen-Cilag, Raritan,
NJ, USA) as previously described [5].
Establishment of T-cell clones
T-cell clones were obtained from CD4
1 cells by limiting dilution at
0.3 cells/well in the presence of a feeder cell mixture and soluble
anti-CD3 mAb (1mg/mL; OKT3, Jansen-Cilag) in X-VIVO 15
medium (BioWhittaker, Verviers, Belgium) supplemented with
5% pooled human AB serum (BioWhittaker), 100IU/mL penicil-
lin/streptomycin (BioWhittaker) as previously described [4].
Cytotoxic assay
Cytotoxicity was assessed in a standard 4h
51Cr release assay, as
previously described [35]. U937, K562, Daudi, and Jurkat target
cell lines used were kindly provided by Dr. K. Fleischhauer. In
some experiments, concanamycin A (CMA, Sigma-Aldrich, St
Louis, MO, USA), Z-AAD-CMK (Calbiochem, San Diego, CA,
USA), anti-HLA-I mAb (clone W/632, BioLegend), anti-HLA-G
mAb (clone 87G, Exbio Praha, Nad Saﬁnou, Czech Republic), and
isotype controls (IgG2a,k, BD Pharmingen, San Diego, CA, USA)
were added at the indicated concentrations.
CD107a/GZB mobilization assay
T-cell degranulation was evaluated in a CD107a ﬂow cytometric
assay, according to a protocol adapted from Alter et al. [36].
Brieﬂy, 10
5 cells from T cells were plated in IMDM (BioWhit-
taker) supplemented with 10% FCS (BioWhittaker), 100IU/mL
penicillin/streptomycin (BioWhittaker), 2mM L-Glutamine
(BioWhittaker), with anti-CD107a mAb (20mL/mL; BD Pharmin-
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of 10
4 cell lines or freshly isolated target cells at 371C. After 3h,
monensin A (Sigma-Aldrich) was added (30mg/mL). After
additional 3h of incubation, cells were washed and stained with
anti-CD4, and anti-GZB mAb. In some cultures anti-HLA-I mAb
(20mg/mL, clone W6/32, BioLegend), anti-HLA-G mAb (20mg/
mL, clone 87G, Exbio Praha), anti-CD18mAb (25mg/mL, clone
TS1/18, BioLegend), anti-CD226 (10mg/mL, clone 102511, R&D
Systems, Minneapolis, MN, USA), and Ig isotype controls
(IgG2a,k, and IgG1, respectively, BD Pharmingen) were added.
510
5 p815 were incubated 30min with 5mg/mL anti-CD2 mAb
(clone RPA-2.10, BD Pharmingen) or 10mg/mL anti-CD226
(clone 102511, R&D Systems) and subsequently washed, before
being used as target cells.
Statistical analysis
Mean values were reported as Mean7SE. Mann–Whitney test
was used to determine the statistical signiﬁcance of the data.
Two-tailed analysis was performed, unless not speciﬁed in the
text. Signiﬁcance was deﬁned as pr0.05; pr0.005; and
pr0.0005. Statistic calculations were performed with the
Prism program 5.0 (GraphPad Software).
Acknowledgements: The authors thank Dr. Michela Comi for
technical support and Dr. Katharina Fleischhauer for providing
some samples of b-thalassemic patients. This work was supported
by grants from the Italian Telethon Foundation (to S. G.) and the
Cariplo Foundation (to M. G. R.).
Conﬂict of interest: The authors declare no ﬁnancial or
commercial conﬂict of interest.
References
1 Bacchetta, R., Bigler, M., Touraine, J. L., Parkman, R., Tovo, P. A., Abrams,
J., de Waal Malefyt, R. et al., High levels of interleukin 10 production in
vivo are associated with tolerance in SCID patients transplanted with
HLA mismatched hematopoietic stem cells. J. Exp. Med. 1994. 179:
493–502.
2 Groux, H., O’Garra, A., Bigler, M., Rouleau, M., Antonenko, S., de Vries,
J. E. and Roncarolo, M. G., A CD41 T-cell subset inhibits antigen-speciﬁc
T-cell responses and prevents colitis. Nature 1997. 389: 737–742.
3 Roncarolo, M. G., Gregori, S., Battaglia, M., Bacchetta, R., Fleischhauer, K.
and Levings, M. K., Interleukin-10-secreting type 1 regulatory T cells in
rodents and humans. Immunol. Rev. 2006. 212: 28–50.
4 Seraﬁni, G., Andreani, M., Testi, M., Battarra, M., Bontadini, A., Biral, E.,
Fleischhauer, K. et al., Type 1 regulatory T cells are associated
with persistent split erythroid/lymphoid chimerism after allogeneic
hematopoietic stem cell transplantation for thalassemia. Haematologica
2009. 94: 1415–1426.
5 Levings, M. K., Sangregorio, R., Galbiati, F., Squadrone, S., de Waal
Malefyt, R. and Roncarolo, M. G., IFN-alpha and IL-10 induce the
differentiation of human type 1T regulatory cells. J. Immunol. 2001. 166:
5530–5539.
6 McHugh, R. S., Whitters, M. J., Piccirillo, C. A., Young, D. A., Shevach,
E. M., Collins, M. and Byrne, M. C., CD4(1)CD25(1) immunoregulatory
T cells: gene expression analysis reveals a functional role for the
glucocorticoid-induced TNF receptor. Immunity 2002. 16: 311–323.
7 Herman, A. E., Freeman, G. J., Mathis, D. and Benoist, C., CD41CD251T
regulatory cells dependent on ICOS promote regulation of effector cells in
the prediabetic lesion. J. Exp. Med. 2004. 199: 1479–1489.
8 Gondek, D. C., Lu, L. F., Quezada, S. A., Sakaguchi, S. and Noelle, R. J.,
Cutting edge: contact-mediated suppression by CD41CD251 regulatory
cells involves a granzyme B-dependent, perforin-independent mechan-
ism. J. Immunol. 2005. 174: 1783–1786.
9 Cao, X., Cai, S. F., Fehniger, T. A., Song, J., Collins, L. I., Piwnica-Worms,
D. R. and Ley, T. J., Granzyme B and perforin are important for regulatory
T cell-mediated suppression of tumor clearance. Immunity 2007. 27:
635–646.
10 Grossman, W. J., Verbsky, J. W., Barchet, W., Colonna, M., Atkinson, J. P.
and Ley, T. J., Human T regulatory cells can use the perforin pathway to
cause autologous target cell death. Immunity 2004. 21: 589–601.
11 Eﬁmova, O. V. and Kelley, T. W., Induction of granzyme B expression in
T-cell receptor/CD28-stimulated human regulatory T cells is suppressed
by inhibitors of the PI3K-mTOR pathway. BMC Immunol. 2009. 10: 59.
12 Czystowska, M., Strauss, L., Bergmann, C., Szajnik, M., Rabinowich, H.
and Whiteside, T. L., Reciprocal granzyme/perforin-mediated death of
human regulatory and responder T cells is regulated by interleukin-2
(IL-2). J. Mol. Med. 2010. 88: 577–588.
13 Kawamura, K., Kadowaki, N., Kitawaki, T. and Uchiyama, T., Virus-
stimulated plasmacytoid dendritic cells induce CD41 cytotoxic regula-
tory T cells. Blood 2006. 107: 1031–1038.
14 Somersalo, K., Anikeeva, N., Sims, T. N., Thomas, V. K., Strong, R. K.,
Spies, T., Lebedeva, T. et al., Cytotoxic T lymphocytes form an antigen-
independent ring junction. J. Clin. Invest. 2004. 113: 49–57.
15 Huang, J. Y., Umehara, H., Inoue, H., Tabassam, F. H., Okazaki, T.,
Kono, T., Minami, Y. et al., Differential interaction of Cbl with Grb2 and
CrkL in CD2-mediated NK cell activation. Mol. Immunol. 2000. 37:
1057–1065.
16 Pende, D., Castriconi, R., Romagnani, P., Spaggiari, G. M., Marcenaro, S.,
Dondero, A., Lazzeri, E. et al., Expression of the DNAM-1 ligands, Nectin-2
(CD112) and poliovirus receptor (CD155), on dendritic cells: relevance for
natural killer-dendritic cell interaction. Blood 2006. 107: 2030–2036.
17 Bottino, C., Castriconi, R., Pende, D., Rivera, P., Nanni, M., Carnemolla, B.,
Cantoni, C. et al., Identiﬁcation of PVR (CD155) and Nectin-2 (CD112) as
cell surface ligands for the human DNAM-1 (CD226) activating molecule.
J. Exp. Med. 2003. 198: 557–567.
18 Akdis, M., Verhagen, J., Taylor, A., Karamloo, F., Karagiannidis, C.,
Crameri, R., Thunberg, S. et al., Immune responses in healthy and
allergic individuals are characterized by a ﬁne balance between allergen-
speciﬁc T regulatory 1 and T helper 2 cells. J. Exp. Med. 2004. 199:
1567–1575.
19 Mandapathil, M., Szczepanski, M. J., Szajnik, M., Ren, J., Jackson, E. K.,
Johnson, J. T., Gorelik, E. et al., Adenosine and prostaglandin E2 cooperate
in the suppression of immune responses mediated by adaptive regulatory
T cells. J. Biol. Chem. 2010. 285: 27571–27580.
20 Middleton, D., Curran, M. and Maxwell, L., Natural killer cells and their
receptors. Transpl. Immunol. 2002. 10: 147–164.
Eur. J. Immunol. 2011. 41: 1652–1662 Immunomodulation 1661
& 2011 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.eji-journal.eu21 Yasukawa, M., Ohminami, H., Arai, J., Kasahara, Y., Ishida, Y. and Fujita,
S., Granule exocytosis, and not the fas/fas ligand system, is the
main pathway of cytotoxicity mediated by alloantigen-speciﬁc CD4(1)
as well as CD8(1) cytotoxic T lymphocytes in humans. Blood 2000. 95:
2352–2355.
22 Zaunders, J. J., Dyer, W. B., Wang, B., Munier, M. L., Miranda-Saksena, M.,
Newton, R., Moore, J. et al., Identiﬁcation of circulating antigen-speciﬁc
CD41T lymphocytes with a CCR51, cytotoxic phenotype in an HIV-1
long-term nonprogressor and in CMV infection. Blood 2004. 103:
2238–2247.
23 Zheng, C. F., Ma, L. L., Jones, G. J., Gill, M. J., Krensky, A. M., Kubes, P. and
Mody, C. H., Cytotoxic CD41T cells use granulysin to kill Cryptococcus
neoformans, and activation of this pathway is defective in HIV patients.
Blood 2007. 109: 2049–2057.
24 van Bergen, J., Thompson, A., van der Slik, A., Ottenhoff, T. H.,
Gussekloo, J. and Koning, F., Phenotypic and functional characterization
of CD4T cells expressing killer Ig-like receptors. J. Immunol. 2004. 173:
6719–6726.
25 Yen, J. H., Moore, B. E., Nakajima, T., Scholl, D., Schaid, D. J., Weyand,
C. M. and Goronzy, J. J., Major histocompatibility complex class
I-recognizing receptors are disease risk genes in rheumatoid arthritis.
J. Exp. Med. 2001. 193: 1159–1167.
26 Shaw, S. and Luce, G. E., The lymphocyte function-associated antigen
(LFA)-1 and CD2/LFA-3 pathways of antigen-independent human T cell
adhesion. J. Immunol. 1987. 139: 1037–1045.
27 Inoue, H., Miyaji, M., Kosugi, A., Nagafuku, M., Okazaki, T., Mimori, T.,
Amakawa, R. et al., Lipid rafts as the signaling scaffold for NK cell
activation: tyrosine phosphorylation and association of LAT with
phosphatidylinositol 3-kinase and phospholipase C-gamma following
CD2 stimulation. Eur. J. Immunol. 2002. 32: 2188–2198.
28 Orange, J. S., Harris, K. E., Andzelm, M. M., Valter, M. M., Geha, R. S. and
Strominger, J. L., The mature activating natural killer cell immunologic
synapse is formed in distinct stages. Proc. Natl. Acad. Sci. USA 2003. 100:
14151–14156.
29 Zheng, X., Wang, Y., Wei, H., Sun, R. and Tian, Z., LFA-1 and CD2
synergize for the Erk1/2 activation in the natural killer (NK) cell
immunological synapse. J. Biol. Chem. 2009. 284: 21280–21287.
30 Tahara-Hanaoka, S., Shibuya, K., Onoda, Y., Zhang, H., Yamazaki, S.,
Miyamoto, A., Honda, S. et al., Functional characterization of DNAM-1
(CD226) interaction with its ligands PVR (CD155) and nectin-2 (PRR-2/
CD112). Int. Immunol. 2004. 16: 533–538.
31 Gilﬁllan, S., Chan, C. J., Cella, M., Haynes, N. M., Rapaport, A. S., Boles, K.
S., Andrews, D. M. et al., DNAM-1 promotes activation of cytotoxic
lymphocytes by nonprofessional antigen-presenting cells and tumors. J.
Exp. Med. 2008. 205: 2965–2973.
32 S e t h ,S . ,G e o r g o u d a k i ,A .M . ,C h a m b e r s ,B .J . ,Q i u ,Q . ,K r e m m e r ,E . ,M a i e r ,M .
K . ,C z e l o t h ,N .e ta l . ,Heterogeneous expression of the adhesion receptor
CD226 on murine NK and T cells and its function in NK-mediated killing
of immature dendritic cells. J. Leukoc. Biol. 2009. 86: 91–101.
33 Gregori, S., Tomasoni, D., Pacciani, V., Scirpoli, M., Battaglia, M.,
Magnani, C. F., Hauben, E. and Roncarolo, M. G., Differentiation of type
1T regulatory cells (Tr1) by tolerogenic DC-10 requires the IL-10-
dependent ILT4/HLA-G pathway. Blood 2010. 116: 935–944.
34 Thomas, D. A. and Massague, J., TGF-beta directly targets cytotoxic T cell
functions during tumor evasion of immune surveillance. Cancer Cell 2005.
8: 369–380.
35 Moretta, A., Bottino, C., Pende, D., Tripodi, G., Tambussi, G., Viale, O.,
Orengo, A. et al., Identiﬁcation of four subsets of human CD3-CD161
natural killer (NK) cells by the expression of clonally distributed
functional surface molecules: correlation between subset assignment of
NK clones and ability to mediate speciﬁc alloantigen recognition. J. Exp.
Med. 1990. 172: 1589–1598.
36 Alter, G., Malenfant, J. M. and Altfeld, M., CD107a as a functional marker
for the identiﬁcation of natural killer cell activity. J. Immunol. Methods
2004. 294: 15–22.
Abbreviations: GZA: granzyme A  GZB: granzyme B  HD: healthy
donor  HSCT: hematopoietic stem cell transplantation  IONO:
ionomycin  KIR: killer cell Ig-like receptors  LFA: lymphocyte
function-associated antigen  PMC: persistent mixed chimerism 
PRF: perforin  SFU: spot forming units  Tr1: type 1 regulatory T 
b-thal: b-thalassemic
Full correspondence: Dr. Silvia Gregori, San Raffaele Telethon Institute
for Gene Therapy (HSR-TIGET), Via Olgettina 58, 20132 Milan, Italy
Fax: 139-02-2643-4668
e-mail: gregori.silvia@hsr.it
Additional correspondence: Maria Grazia Roncarolo, San Raffaele
Telethon Institute for Gene Therapy (HSR-TIGET), via Olgettina 58,
20132 Milan, Italy
e-mail: m.roncarolo@hsr.it
Received: 30/9/2010
Revised: 12/2/2011
Accepted: 25/3/2011
Accepted article online: 6/4/2011
Eur. J. Immunol. 2011. 41: 1652–1662 Chiara F. Magnani et al. 1662
& 2011 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.eji-journal.eu